Evidence map›Paper›PMID 35602243›Full record

ArticleF1000Research2022

eTRANSAFE: Building a sustainable framework to share reproducible drug safety knowledge with the public domain.

Sirarat Sarntivijai, Niklas Blomberg, Katharina B Lauer, Katharine Briggs, Thomas Steger-Hartmann, Johan van der Lei, John-Michael Sauer, Richard Liwski, Miranda Mourby, Montse Camprubi and 1 more

Abstract read
In one paragraph

Article in F1000Research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sirarat SarntivijaiELIXIR Hub, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.ORCID 0000-0002-2548-641X
Niklas BlombergELIXIR Hub, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
Katharina B LauerELIXIR Hub, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.ORCID 0000-0002-4347-7525
Katharine BriggsLhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK.ORCID 0000-0002-2044-1159
Thomas Steger-HartmannBayer AG, Research & Development, Pharmaceuticals, Investigational Toxicology, 13342 Berlin, Germany.
Johan van der LeiDepartment of Medical Informatics, Erasmus University Rotterdam, EUR - Erasmus Medical Center (MC), Rotterdam, The Netherlands.
John-Michael SauerPredictive Safety Testing Consortium, Critical Path Institute, Tucson, Arizona, 85718, USA.
Richard LiwskiPredictive Safety Testing Consortium, Critical Path Institute, Tucson, Arizona, 85718, USA.
Miranda MourbyCentre for Health, Law and Emerging Technologies (HeLEX), Faculty of Law, University of Oxford, Oxford, OX2 7DD, UK.
Montse CamprubiSynapse Research Management Partners S.L., C. Diputació 237, Àtic 3a, 08007, Barcelona, Spain.
eTRANSAFE Consortium

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Integrative drug safety research in translational health informatics has rapidly evolved and included data that are drawn in from many resources, combining diverse data that are either reused from (curated) repositories, or newly generated at source. Each resource is mandated by different sets of metadata rules that are imposed on the incoming data. Combination of the data cannot be readily achieved without interference of data stewardship and the top-down policy guidelines that supervise and inform the process for data combination to aid meaningful interpretation and analysis of such data. The eTRANSAFE Consortium's effort to drive integrative drug safety research at a large scale hereby present the lessons learnt and the proposal of solution at the guidelines in practice at this Innovative Medicines Initiative (IMI) project. Recommendations in these guidelines were compiled from feedback received from key stakeholders in regulatory agencies, EFPIA companies, and academic partners. The research reproducibility guidelines presented in this study lay the foundation for a comprehensive data sharing and knowledge management plans accounting for research data management in the drug safety space - FAIR data sharing guidelines, and the model verification guidelines as generic deliverables that best practices that can be reused by other scientific community members at large. FAIR data sharing is a dynamic landscape that rapidly evolves with fast-paced technology advancements. The research reproducibility in drug safety guidelines introduced in this study provides a reusable framework that can be adopted by other research communities that aim to integrate public and private data in biomedical research space.

Indexed as

Biomedical ResearchPublic SectorInformation DisseminationMetadataReproducibility of Resultsdata sharingDrug SafetyeTRANSAFEFAIR DataInteroperabilitymodel validationResearch reproducibility

Identifiers

PMID35602243
PMCPMC9096149

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.